Patents by Inventor Ching-Yi Chang

Ching-Yi Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250090496
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: April 5, 2024
    Publication date: March 20, 2025
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
  • Publication number: 20250064757
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: April 8, 2024
    Publication date: February 27, 2025
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • Publication number: 20240414887
    Abstract: A temperature adjustment module is provided. The temperature adjustment module includes a temperature changing module and a temperature control module. The temperature changing module includes a temperature changing area. The temperature changing module is in contact with a peripheral circuit element on a motherboard through the temperature changing area and a heat conduction material. The temperature control module is electrically connected to the temperature changing module and configured to control a temperature of the temperature changing module to reach a target temperature. The temperature changing module further includes a printed circuit board in the temperature changing area, and the temperature of the temperature changing module is changed by at least one of a winding wire or an electronic component on the printed circuit board.
    Type: Application
    Filed: February 27, 2024
    Publication date: December 12, 2024
    Applicant: GIGA-BYTE TECHNOLOGY CO.,LTD.
    Inventors: Chih-Hua Ke, Hung-Cheng Chen, Tse-Hsien Liao, Ching-Yi Chang
  • Publication number: 20240414834
    Abstract: A temperature adjustment module and a temperature adjustment method are provided. The temperature adjustment module includes a temperature control module, a temperature changing module, and a temperature sensor. The temperature changing module is in contact with a peripheral circuit element and electrically connected to the temperature control module. The temperature sensor is in contact with the peripheral circuit element and electrically connected to the temperature control module. When a cool down module on a main circuit element of a mother board cools down the main circuit element, the temperature sensor detects a peripheral temperature of the peripheral circuit element. The temperature control module determines whether the peripheral temperature is lower than or higher than a target temperature to determine whether to operate the temperature changing module to perform temperature adjustment on the peripheral circuit element.
    Type: Application
    Filed: February 27, 2024
    Publication date: December 12, 2024
    Applicant: GIGA-BYTE TECHNOLOGY CO.,LTD.
    Inventors: Chih-Hua Ke, Hung-Cheng Chen, Tse-Hsien Liao, Ching-Yi Chang
  • Publication number: 20240398831
    Abstract: Disclosed herein are compositions and methods for treating cancer. The methods may include administering to a subject at least one estrogen receptor (ER) modulating drug. The methods may further include administering to the subject at least one additional therapy. Further provided herein are methods of predicting response of a subject to immune checkpoint blockade (ICB) therapy.
    Type: Application
    Filed: October 5, 2022
    Publication date: December 5, 2024
    Inventors: Donald McDonnell, Binita Chakraborty, Ching-Yi Chang, Jovita Byemerwa
  • Publication number: 20240366534
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: July 4, 2024
    Publication date: November 7, 2024
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • Patent number: 11980597
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 14, 2024
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Patent number: 11974983
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: May 7, 2024
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Publication number: 20230233490
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: March 30, 2023
    Publication date: July 27, 2023
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • Publication number: 20230157995
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: September 22, 2022
    Publication date: May 25, 2023
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
  • Patent number: 11497730
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 15, 2022
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Patent number: 11467403
    Abstract: An operating method of an electronic system is provided. The operating method of the electronic system includes generating a first user input by a first input device and performing a first input control according to the first user input during a first input operation mode, determining whether a light intersection point of a ray emitted by a second input device with a virtual reality (VR) environment exists in the VR environment, switching to a second input operation mode in response to determining that the light intersection point of the ray with the VR environment exists in the VR environment and generating a second user input by the second input device and performing a second input control according to the second user input during the second input operation mode.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: October 11, 2022
    Assignee: HTC Corporation
    Inventor: Ching-Yi Chang
  • Publication number: 20220057634
    Abstract: An operating method of an electronic system is provided. The operating method of the electronic system includes generating a first user input by a first input device and performing a first input control according to the first user input during a first input operation mode, determining whether a light intersection point of a ray emitted by a second input device with a virtual reality (VR) environment exists in the VR environment, switching to a second input operation mode in response to determining that the light intersection point of the ray with the VR environment exists in the VR environment and generating a second user input by the second input device and performing a second input control according to the second user input during the second input operation mode.
    Type: Application
    Filed: August 20, 2020
    Publication date: February 24, 2022
    Inventor: Ching-Yi Chang
  • Publication number: 20220031658
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: April 9, 2018
    Publication date: February 3, 2022
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
  • Publication number: 20210361596
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 25, 2021
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Patent number: 10905659
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: February 2, 2021
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Publication number: 20190231718
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women, and in particular embodiments, methods for treating ER+ cancers having gain of function mutations in the ESR1 ligand binding domain, with an effective amount of a compound selected from the group consisting of raloxifene, bazedoxifene, tamoxifen, etacstil, and fulvestrant, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: October 10, 2017
    Publication date: August 1, 2019
    Inventors: Kaitlyn ANDREANO, Ching-yi CHANG, Donald P. MCDONNELL, Stephanie L. GAILLARD
  • Publication number: 20190151286
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: February 1, 2019
    Publication date: May 23, 2019
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Patent number: 10258604
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 16, 2019
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Publication number: 20180221335
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 9, 2018
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard